In a clinical study of 71 PC patients, Notch3 was identified as a novel biomarker for predicting the efficacy of gemcitabine (GEM), whereby low Notch3 expression was associated with better GEM treatment efficacy and longer OS of PC patients (Eto et al., 2013). The gene discussed is NOTCH3; the disease is pachyonychia congenita.